Daily filing brief

10 Important BSE and NSE Announcements — 9 August 2026

By Daily BrieferPublished

Here are 10 notable company announcements from 9 August 2026. The brief brings the key developments together in one place and keeps the essential details easy to scan.

  1. Gland Pharma Ltd

    Gland Pharma Announces Strategic CDMO Manufacturing Agreement with Global Pharmaceutical Company

    Press Release / Media Release

    Deal overview

    • Strategic CDMO partnership with a global pharma company; Manufacturing and Supply Agreement for sterile injectables.

    Scope and offerings

    • 55 SKUs across three sites; technology transfer, development, and long-term supply.

    One-stop CDMO solution

    • Integrated development, technology transfer, manufacturing, and regulatory support for partner.

    Financial outlook

    • Annual revenue potential of USD 90-100 million post-commercialization.

    Timeline

    • Technology transfer expected within two years; revenues from calendar year 2029.

    Strategic rationale

    • Strengthens Gland Pharma's position as an end-to-end sterile injectables CDMO.
    View source

  2. DOMS Industries Ltd

    DOMS Industries Q1 FY27: Revenue up 19.2% to INR670 crores; margins pressured by RM volatility; Reynolds integration and 50-acre capex underway; guidance 18-20% growth

    Earnings Call Transcript

    Financial Performance

    • Revenue rose 19.2% to INR670 crores in Q1 FY27.
    • EBITDA fell 16.4% to INR82.6 crores; margin 12.3%.
    • PAT declined to INR45.3 crores; PAT margin 6.8%.
    • Gross margins declined about 400 basis points due to raw material inflation.
    • ESOP-related costs and channel-partner events reduced margins by ~0.4 percentage points.

    Capacity Expansion and Reynolds Integration

    • 50+ acre greenfield project development is on track; commissioning ~300,000 sq ft by Q2 FY27.
    • Invested close to INR100 crores in Q1 FY27 toward capital investments.
    • Reynolds asset acquisition completed; Umbergaon asset movement completed; full sales potential unlocked over time.
    • Reynolds had about INR130-140 crores revenue in the previous year.
    • Reynolds to operate in parallel; capacity growth will come from planned expansions, not extra volumes.
    • Target ASP uplift from Reynolds; some capacity diverted to Reynolds products.
    • Plans to launch diaries and paper stationery under Reynolds.

    Guidance and Outlook

    • Guidance remains 18-20% consolidated sales growth; margin visibility limited due to RM volatility.
    • No further price hikes planned in the current quarter.
    • FY28 margin target around mid-teens; requires RM normalization.
    • Capex cadence discussed; annual plan around INR200-250 crores; execution space constraints.

    Pricing and Margin Dynamics

    • Average price rise in Q1 was 4-5%.
    • Average RM price increase was about 20% with 10-11% consumption growth.
    • About 500 bps of pass-through remains to be captured.
    • Current quarter not planning further price hikes; volatility to settle before decisions.
    • Management will add value to products without sacrificing margins.

    Exports and Geography

    • Export growth was flat in Q1 FY27; headwinds.
    • Exports contribute about 12% of revenue.
    • West Asia disruptions caused longer transit times and higher freight.
    • West India revenue declined to about INR140 crores YoY from INR186 crores.

    Operations and Capital Allocation

    • 3x sales per INR invested; historically around 2.7x last year.
    • 18-24 months to reach full production capacity.
    • Jammu site added 11+ acres; additional land acquisitions.
    • 50-acre plant and adjacent expansions to serve both brands.

    Q&A Highlights

    • Margin trajectory discussed; pricing calibrated to protect market share.
    • Reynolds is brand expansion with ASP uplift but limited volume growth.
    • Industry pricing aligned with peers; no aggressive hikes.
    • ESOP costs for FY27 ~INR10 crores; may rise in FY28.
    View source

  3. Quality Power Electrical Equipments Ltd

    Quality Power Q1 FY2027 revenue up 32% to ₹2,564 million; order book ₹19,455 million and expansion plans disclosed

    Press Release / Media Release

    Financial highlights

    • Total revenue for Q1 FY2027: ₹2,564 million, up 32.1% YoY.
    • Adjusted EBITDA: ₹725 million; margin 28.3%.
    • Profit after tax (adjusted): ₹545 million; margin 21.3%.
    • Reported PBT ₹594 million; PAT ₹467 million.
    • Order book ₹19,455 million; ~1.9x FY2026 revenue.
    • Interim dividend declared for FY2027: ₹0.25 per equity share.
    • Proposed acquisition of Winwin Speciality Insulators Limited progressing; EV ~₹315 crore.
    • Sangli manufacturing expansion on track; trial production targeted August 2026.
    • Endoks Turkey expansion: civil work complete; interior fit-out; European operations start Q3 FY2027.
    • HVDC CTC magnet wire facility: machinery installation to commence August 2026.
    • Appointment of Shylendra Kumar as Group CTO.
    • Ind AS 29 adjustment: ₹78.21 million net monetary loss; adjusted measures presented.
    • Order book by subsidiary: Endoks ₹8,010 Mn; Mehru ₹5,850 Mn; Quality Power ₹5,530 Mn.

    Strategic developments

    • Winwin Speciality Insulators acquisition: term sheet executed June 2026; EV ~₹315 crore.
    • Q1 order wins: US data centre HV reactors; Japan FACTS system; India instrument transformers.
    • Endoks Turkey expansion: civil complete; interior fit-out; European operations start Q3 FY2027.
    • Sangli manufacturing expansion: machinery installation underway; trial production August 2026.
    • HVDC magnet wire facility: machinery installation to commence August 2026.
    • Shylendra Kumar appointed Group CTO.
    • Interim dividend: ₹0.25 per share.

    Outlook and execution

    • Outlook: robust long-term demand for grid modernization and energy transition.
    • Execution and supply chain resilience remain priority amid raw material constraints.
    View source

  4. Sky Gold And Diamonds Ltd

    Sky Gold and Diamonds reports Q1 FY27 standalone and consolidated results; subsidiary fraud disclosed

    Financial Results

    Standalone results

    • Standalone revenue from operations: Rs 1,44,004.43 lakh.
    • Standalone total income: Rs 1,44,692.05 lakh.
    • Standalone PBT: Rs 8,180.32 lakh.
    • Standalone PAT: Rs 6,058.76 lakh.
    • Standalone EPS: Basic Rs 3.91; Diluted Rs 3.91.
    • Standalone India revenue: Rs 1,23,072.92 lakh.
    • Standalone outside India revenue: Rs 20,931.51 lakh.
    • Standalone results reviewed by statutory auditors with unmodified opinion.
    • Board approved standalone results on 9 August 2026.
    • Single operating segment: gold jewellery.

    Consolidated results

    • Consolidated revenue from operations: Rs 2,01,279.39 lakh.
    • Consolidated total income: Rs 2,02,074.77 lakh.
    • Consolidated PBT: Rs 13,480.33 lakh.
    • Consolidated PAT: Rs 10,490.19 lakh.
    • Consolidated EPS: Basic Rs 6.67; Diluted Rs 6.66.
    • Consolidated India revenue: Rs 1,63,694.26 lakh.
    • Consolidated outside India revenue: Rs 37,585.13 lakh.
    • Consolidated results reviewed by statutory auditors with unmodified opinion.
    • Group operates a single segment: gold jewellery.

    Post-quarter event

    • Fraud incident at Starmangalsutra Private Limited caused up to Rs 1,070.00 lakh loss.
    • Investigation ongoing; cyber fraud involved unauthorized transfers.
    • Measures to strengthen employee awareness, verification procedures and internal controls implemented.
    View source

  5. IDFC First Bank Ltd

    IDFC FIRST Bank Integrated Annual Report FY2025-26 – Investor Highlights

    Reg. 34 (1) Annual Report

    Financial Performance

    • Total consolidated income ₹48,422.39 crore.
    • Consolidated PAT ₹1,610 crore.
    • Loans and advances ₹2.84 lakh crore, up 20% YoY.
    • Deposits ₹2.94 lakh crore.

    Capital & Capital Adequacy

    • CAR 15.05%.
    • CET1 13.33%.

    Dividend & Corporate Actions

    • Proposed dividend ₹0.25 per equity share.
    • Amalgamation of eIDFC into Bank effective Oct 1, 2024.

    Additional Capital Actions

    • Equity raise up to ₹7,500 crore.
    • Debt issuance up to ₹12,500 crore.
    View source

  6. Deepak Fertilisers & Petrochemicals Corporation Ltd

    Deepak Fertilisers & Petrochemicals FY2025-26 Annual Report: Strength at the Core, Value Built to Soar

    Reg. 34 (1) Annual Report

    Financial performance

    • Consolidated revenue from operations: ₹11,506 crore, up 12% YoY.
    • Operating EBITDA: ₹1,684 crore; Profit after tax: ₹739 crore.
    • PAT margin: 6.4%; EBITDA margin: 14.6% (consolidated).
    • Net debt to equity: 0.67x; DSCR: 1.12x.
    • Consolidated earnings per share: ₹58.40; ROE declined vs prior year.
    • Operating cash flow supported by disciplined working capital management.

    Growth & strategy

    • Transforming from a products company to a solutions platform across CNB, IC, and Mining.
    • Investing in capacity, backward integration, digitalisation, and supply-chain resilience.
    • Key acquisitions to strengthen mining solutions: Chardham Chemicals and 100% PBS platforms.
    • LNG-to-ammonia integration and TAN/N nitric acid expansions to enhance margin resilience.
    • Strategic LNG regasification and novation of LNG supply with Equinor to DGPL.

    Key projects & capacity

    • Gopalpur TAN: 376 KTPA; ~95% complete; commissioning expected H2 FY2026-27.
    • Dahej Nitric Acid expansion: WNA 300 KTPA, CNA 150 KTPA; ~86% complete.
    • Post-commissioning, Group TAN capacity ~1 MTPA, addressing ~60% of domestic TAN demand.
    • Dahej CN A expansion to support broader downstream nitration and mining needs.
    • Two flagship projects approach commissioning to translate capex into volumes and earnings.

    Capital structure & liquidity

    • Net debt in FY2025-26: ₹4,99,001 lakh; gearing 0.67x.
    • Bank borrowings: total facilities used ₹4,117 crore; unused ₹1,281 crore.
    • WC facilities used ₹902 crore; unused ₹1,544 crore.
    • CCDs of ₹80,000 lakh issued by DMSL; equity component recognised in OCI/NCI.
    • End-FY liquidity supported by ₹37,771 lakh cash & cash equivalents.

    Governance & ESG

    • Dr Purvi Mehta Bhatt appointed Independent Woman Director (from Jan 1, 2026).
    • Yeshil Sailesh Mehta appointed Non-Executive Non-Independent Director (from Jul 1, 2026).
    • IsFon CSR: 63,076 beneficiaries; CSR spend ₹327.27 lakh; shortfall ₹419 lakh carried forward.
    • CSR shifted from Skill Development Centre to Centre of Excellence; governance and policy disclosures on company site.
    • NFRA/secretarial audits; robust internal controls; board committees active with regular oversight.

    Dividend & shareholder matters

    • Forty-sixth AGM on 1 Sept 2026 via VC/OAVM; e-voting enabled.
    • Dividend proposed: ₹10 per equity share (face value ₹10); payout date on or before 30 Sept 2026.
    • Share dematerialisation: ~97.75% of shares in demat form; benefit from faster trading.
    • Unclaimed dividends/shares as per IEPF framework; claim window and process detailed in annual report.

    Risks & outlook

    • Global macro: IMF/IMF-linked trends; India growth supports chemicals, mining, and agri inputs.
    • Raw material volatility and energy costs; potential subsidy and policy shifts in fertilisers.
    • Geopolitical tensions and supply-chain disruptions; currency/commodity price fluctuations.
    • Execution risk on large capex (TAN/NA) and integration of acquisitions; regulatory approvals timing.
    View source

  7. Medi Assist Healthcare Services Ltd

    Medi Assist Q1 FY27: Revenue Up 24.1%; Paramount Integration Near Closure; AI Contracts Signed; International Platform Established

    Press Release / Media Release

    Financial Highlights

    • Operating revenue ₹236.5 Cr, +24.1% YoY.
    • EBITDA ₹48.0 Cr, 20.3% margin; down 175 bps YoY.
    • Reported PAT ₹27.6 Cr, 11.2% margin; +21.9% YoY.
    • Adjusted PAT ₹24.5 Cr; +8.2%.
    • India Health PUM ₹8,975 Cr, +26.8% YoY.
    • Group market share 37.6%; +440 bps YoY.
    • Technology revenue ₹7.8 Cr, +55.5% YoY.
    • Free Cash ₹245.5 Cr (C&CE).
    • Debt-free balance sheet.

    Strategic & Operational Developments

    • Paramount integration at logical close; 95%+ group claims migrated.
    • AI platform contracts signed with seven insurers.
    • Mayfair ownership 91.75%; international platform established.
    • Thailand first tech deployment live from 1 July 2026.
    • Nikhil Chopra appointed to lead international business full-time.
    • Q1 international revenue ₹10.1 Cr; -5.2% YoY.

    Governance Changes

    • Dr. Vikram Jit Singh Chhatwal becomes Non-Executive, Non-Independent Director and Chairman.
    • Gaurav Bhatnagar appointed Chief TPA Officer; designated SMP.

    Outlook & Financial Position

    • Q2 FY27 to run three active tracks.
    • Tech licensing and international platforms to improve EBITDA margins.
    • Growth funded entirely from operating cash flows; no external capital.
    • Contract liabilities ₹337.4 Cr at 30 Jun 2026.
    • Balance sheet snapshot: Debt-free; Net worth ₹884.1 Cr as of 30 Jun 2026.
    View source

  8. Sky Gold And Diamonds Ltd

    Sky Gold and Diamonds reports Q1 FY27 revenue growth; appoints CEO; raises FY27 guidance

    Investor Presentation

    Business Overview

    • Core business: lightweight gold and diamond jewellery for B2B retailers.
    • Exports focus with London expo; initial UK/Europe orders ₹30–45 cr.
    • Advance Gold model reduces working capital; target ~30% volumes by FY30.
    • Vision 2030 Sky Gold 3.0 prioritizes cash generation and governance.

    Financial Performance

    • Q1 FY27 revenue ₹2,012.8 cr; YoY +77.9%.
    • Q1 FY27 EBITDA ₹156.7 cr; margin 7.8%.
    • Q1 FY27 PAT ₹104.9 cr; margin 5.2%.
    • FY26 revenue ₹6,294.9 cr; EBITDA ₹434.3 cr; PAT ₹281.8 cr.
    • FY27 guidance: revenue ₹8,100 cr; EBITDA margin 7.0–7.5%; PAT margin 4.5–4.75%.

    Operational Highlights

    • Appointed Akash Talesara as CEO.
    • Showcased at Asiana UK-India Expo, London; initial orders ₹30–45 cr.
    • Value-added share rose to 50–55% in FY26, driving margin expansion.
    • Advance Gold volumes ~30% by FY30; zero working capital inventory.
    • Manufacturing footprint expanded to 135,000 sq ft; Dubai office opened; MSKA appointed.

    Capital Structure & Liquidity

    • Total equity as of 31-Mar-26: ₹1,205.9 cr; share capital ₹154.9 cr.
    • Total assets ₹2,195.2 cr; current assets ₹1,636.1 cr.
    • Total borrowings ₹847.9 cr (non-current ₹48.1 cr; current ₹799.8 cr).
    • Cash and cash equivalents ₹7.9 cr; net current assets ~₹712.5 cr.
    • Operating cash flow FY26: ₹44.9 cr negative; financing cash flow ₹171.0 cr.

    Strategic Priorities & Outlook

    • FY30 guidance: revenue ₹18,000–₹19,000 cr; PAT margin ~5.25%+; ROCE 27%+.
    • Growth drivers: higher export mix, value-added jewellery, and advanced gold adoption.
    • FY27 guidance revised upwards; focus on margin expansion and capital efficiency.
    • Dubai expansion and new geographies to broaden export footprint.

    Governance & Leadership

    • Promoters adopt dividend-only compensation; no salaries from FY27.
    • MSKA & Associates LLP appointed as Statutory Auditors.
    • Onboarded BDO for enhanced financial reporting and governance.
    • Board strengthened with industry veterans; leadership hires across domains.
    • CEO appointment: Akash Talesara; background in gems and jewellery.
    View source

  9. Kwality Pharmaceuticals Ltd

    Kwality Pharmaceuticals Limited — Annual Report 2025-26 overview for investors

    Reg. 34 (1) Annual Report

    Financial performance

    • Standalone revenue from operations ₹503.06 crore; Consolidated ₹503.08 crore.
    • PAT ₹67.35 crore; up from ₹39.89 crore last year.
    • EBITDA margin 19.97%; net profit margin 13.39%.
    • PBT ₹89.49 crore; PAT growth ~68.8% YoY.
    • Dividend not declared for FY26.
    • Net cash from operations ₹16.60 crore; investing ₹34.91 crore.
    • Financing cash flow ₹7.04 crore; overall cash decreased ₹11.28 crore.
    • DSIR-recognized in-house R&D; ₹60 lakh invested; 40+ BE molecules; three monoclonal antibodies.
    • FY27 guidance raised to >₹700 crore; long-term target ₹1,000 crore by FY29.
    • EPS ₹64.90; ROE benefited by higher profitability.

    Operations & strategy

    • Single pharmaceutical-formulations segment; 1,000+ products across 25+ therapies.
    • Global footprint: 70+ countries; EU-GMP approved manufacturing; 5 facilities; Unit 6 hormones under construction.
    • Bioequivalence program spanning 40+ oral solid molecules; three monoclonal antibodies in development.
    • Erythropoietin (Kwalipoietin) BE program pre-clinical done; track for CY2027 launch subject to approvals.
    • Significant regulatory audits completed; focus on enhanced regulatory readiness.
    • Exhibited presence at 15+ global pharma events to deepen direct customers.
    • Strategic capex on hormone facility and oncology/biologics capacity expansion; automation upgrades.

    Capital structure & liquidity

    • Standalone equity ₹333.37 crore; Consolidated equity ₹329.92 crore.
    • Share capital ₹10.38 crore; no change in paid-up capital FY26.
    • Long-term borrowings ₹29.40 crore; short-term borrowings ₹101.06 crore.
    • Debt-equity ratio ~0.40; interest coverage 9.15x; operating margin 19.97%; net margin 13.39%.
    • Current ratio 1.80; cash and cash equivalents ₹0.74 crore.
    • Africa subsidiary Kwality Africa Limitada: 51% held; turnover small; year-end loss.

    Governance & risk

    • Independent director Swanith Kapoor appointed June 2, 2026; term five years.
    • Resignations: Kiran Kumar Verma (July 26, 2025); Kartik Kapur (June 2, 2026); Pankaj Takkar and Ravi Shanker Singh.
    • Board meetings held: 12; Audit Committee meetings: 5; Nomination & Remuneration: 4; CSR: 1.
    • Audit Committee chair changed to Bhavesh Mahajan from Feb 1, 2026; KMP changes noted.
    • Secretarial audit by M/s Rishi Mittal & Associates; no qualifications reported.
    • Risk management framework in place; ongoing monitoring of regulatory, product, and FX risks.

    Dividends, shareholding & related party transactions

    • Dividend for FY26: not declared; focus on reinvestment and growth.
    • Promoters hold 54.87%; FPIs 2.79%; Indian public 32.30%; NRIs 7.49%.
    • Related party transactions reported; arm's-length; remuneration to directors disclosed; policy on RPTs.
    • Postal ballot approved appointments of two independent directors (Bedi and Mahajan) on March 28, 2026.

    CSR & ESG

    • CSR expenditure ₹74.30 lakh; 2% average net profit requirement ₹74.30 lakh.
    • One CSR asset created: School building for special children; cost ₹15.75 lakh.
    • ₹30.93 lakh utilized from Unspent CSR account in FY2025-26.

    Subsidiaries & group

    • Kwality Africa Limitada (Mozambique) is 51% owned; turnover and losses modest in year.
    • Group consolidated results include Africa subsidiary; Form AOC-1 disseminates subsidiary details.

    Audit & governance flags

    • Statutory auditors: Vijay Mehra & Co.; no qualifications; term through 2029.
    • Secretarial auditors: Rishi Mittal & Associates; five-year term; no qualifications.
    • Independent Directors meeting held; declarations of independence obtained; compliance with governance norms.
    View source

  10. Knack Packaging Ltd

    Knack Packaging Q1 FY27 revenue up 41% YoY; capacity expanded, EBITDA up 53%

    Press Release / Media Release

    Financial highlights

    • Revenue from operations for Q1 FY27 ₹2,624.59 mn, up 41% YoY.
    • EBITDA ₹591.73 mn, up 53% YoY; margin 22.35%.
    • PAT ₹305.28 mn, up 48% YoY; margin 11.53%.
    • ROCE 54.73%, ROE 37.45% for the quarter.

    Capacity expansion

    • Installed capacity increased from 43,300 to 48,000+ MT per annum.
    • Commissioning of new rented facilities augmented manufacturing capacity.

    Strategic developments

    • On-boarding globally renowned brands in domestic and international markets.
    • Serving 28+ industries with 5–50 kg packaging solutions.
    • Exports to over 74 countries.

    Outlook and management commentary

    • Positive about onboarding global brands; expanding footprint and capabilities.
    • Positioned to respond faster to demand across domestic and international markets.
    View source